Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Talazoparib in Japanese Patients With Advanced Solid Tumors
jRCT2080223717Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of talazoparib in Nonhematologic neoplasms and breast cancer (2 arms), sponsored by Pfizer. Primary endpoints: Safety and tolerability of talazoparib and Pharmacokinetics of talazoparib. Started Nov 2017; status: completed.
02
Drugs
talazoparib
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on jRCT2080223717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223717.